Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Open-label, Dose-finding and Dose-expansion, Phase 1b Trial

Eur Urol. 2019 Apr;75(4):697-698. doi: 10.1016/j.eururo.2018.12.018. Epub 2018 Dec 21.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Axitinib
  • Carcinoma, Renal Cell*
  • Humans
  • Kidney Neoplasms*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Axitinib
  • avelumab